Skip to main content
OpenTrials
Completed

NCT Number: NCT01142908

Cardiovascular Intervention Improvement Telemedicine Study

Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have > 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Durham VA Medical Center, Durham, NC

Durham, North Carolina, 27705-3875, United States

About this study

Anticipated Impacts on Veteran's Healthcare: Cardiovascular disease (CVD) is the leading cause of death in the U.S.; more than 80% of veterans have > 2 risk factors for CVD. An intervention that addresses multiple CVD risk factors among high-risk veterans has the greatest potential to improve morbidity and mortality.

Project Background/Rationale: The proposed study will take place in two VA primary care clinics (1-Community-Based Outpatient Clinics and 1-primary care clinic affiliated with a hospital). We will improve CVD risk among veterans by addressing the modifiable risk factors of systolic blood pressure (SBP), smoking, and low-density lipoprotein cholesterol (LDL-C). The intervention will be tailored to the needs of vulnerable high risk patients (e.g. African Americans, low literate) and integrated into clinics, thereby enhancing the potential for benefit and generalizability to other settings.

The proposed study could significantly improve CVD risk management among veterans for several reasons: 1) This intervention is a novel extension of our previous efficacious interventions, but provides a novel extension to address multiple chronic conditions contributing to CVD risk. 2) The intervention focuses on both multiple CVD-related behaviors and medication management. 3) The intervention was developed to ensure implementation across a large and representative sample of veterans; and; 4) The intervention, if found efficacious and financially self-sustaining, could be widely implemented within the VA healthcare system.

Project Objectives: The proposed study will examine two research questions:

  • Can patients randomized to a clinical pharmacist-administered telephone behavioral/ medication management intervention tailored to their needs improve CVD outcomes relative to a control group over 12 months? Primary Hypothesis: (H1) Veterans who receive the behavioral/medication intervention will have greater improvement of their CVD Risk Profile over the 12 months of follow-up as compared to the control group.

Secondary Hypotheses: (H2) Veterans who receive the intervention will have improved medication adherence, physical activity, improved diet, lower body mass index as compared to the control group over 12 months of follow-up. (H3) Veterans who receive the intervention will have greater improvements in LDL over the 12 months of follow-up as compared to the control group. (H4) Veterans with diabetes who receive the intervention will have greater improved HbA1c as compared to the control group over 12 months of follow-up.

  • If the intervention is found to be effective, is it cost effective? Project Methods: To address these hypotheses, we propose a two-arm randomized clinical trial design in which 500 patients with cardiovascular disease will be randomized to either the education control group or the intervention group. Patients randomized to the intervention group will receive a clinical pharmacist-administered intervention, which focuses on behavioral and a medication management. The intervention will occur over 12 months. Patients randomized to the control group will receive educational material about CVD reduction. Given the national prevalence of CVD and the dismal rates of risk factor control, intensive, but easily disseminated interventions such as the one proposed could significantly improve treatment of this epidemic in the VA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Enrolled in one of three Durham Veterans Affairs Medical Center (DVAMC) Primary Care Clinics affiliated with the hospital or the Raleigh Community-Based Outpatient Clinic (CBOC) for at least one year;
  • At least one visit to a primary care physician (PCP) at the Raleigh CBOC or Durham Veterans Affairs Medical Center (VAMC) associated primary care clinics in the previous 12 months;
  • Outpatient diagnostic code for hypertension and/or hypercholesterolemia and lab values indicating either poorly controlled BP levels (>150/90 Hg) AND/OR LDL (>130mg/dl) in the previous year.

Exclusion criteria

  • diagnosed with metastatic cancer,
  • diagnosed with dementia,
  • active diagnosis of psychosis,
  • treated with dialysis,
  • most recent creatinine lab level >2.5 or no creatinine lab value within past year
  • hospitalized for a stroke, heart attack, or had surgery for blocked arteries in the past 3 months,
  • participating in another interventional trial,
  • not currently receiving care at the Durham VAMC or the Raleigh CBOC
  • resident of a nursing home,
  • hard time seeing type/printing on books, magazines articles, etc.
  • hard time hearing on the telephone
  • limited/no access to telephone
  • plans to move medical care from DVAMC or Raleigh CBOC in next 12 months
  • CVD care is currently being managed by a clinical pharmacist
  • HbA1C value in the last 90day > 10% and patient is currently not on an insulin regimen.

Treatment and study plan

Pharmacist CVD

Behavioral

clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.

Primary outcomes

  1. Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)

    Time frame: Baseline

    Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.

  2. Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)

    Time frame: 6 months

    Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.

  3. Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)

    Time frame: 12 months

    Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point [combination of administrative med data pull and self-report at assessment]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.

Secondary outcomes

  1. Mean Systolic Blood Pressure

    Time frame: Baseline

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  2. Mean Systolic Blood Pressure

    Time frame: 6 months

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  3. Mean Systolic Blood Pressure

    Time frame: 12 months

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  4. Mean Diastolic Blood Pressure

    Time frame: Baseline

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  5. Mean Diastolic Blood Pressure

    Time frame: 6 months

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  6. Mean Diastolic Blood Pressure

    Time frame: 12 months

    Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews

  7. Medication Non-adherence

    Time frame: Baseline

    First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.

  8. Medication Non-adherence

    Time frame: 6 months

    First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.

  9. Medication Non-adherence

    Time frame: 12 months

    First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.

  10. Cholesterol LDL

    Time frame: Baseline

    Collected during interview visit by lab personnel

  11. Cholesterol LDL

    Time frame: 6 months

    Collected during interview visit by lab personnel

  12. Cholesterol LDL

    Time frame: 12 months

    Collected during interview visit by lab personnel

  13. Body Mass Index

    Time frame: Baseline

    Calculated from vitals (height & weight) obtained during interview

  14. Body Mass Index

    Time frame: 6 months

    Calculated from vitals (height & weight) obtained during interview

  15. Body Mass Index

    Time frame: 12 months

    Calculated from vitals (height & weight) obtained during interview

  16. HBA1C in Diabetic Patients

    Time frame: Baseline

    Lab values collected at interview visit by lab personnel

  17. HBA1C in Diabetic Patients

    Time frame: 6 months

    Lab values collected at interview visit by lab personnel

  18. HBA1C in Diabetic Patients

    Time frame: 12 months

    Lab values collected at interview visit by lab personnel

Sponsors and collaborators

Lead sponsor

VA Office of Research and Development

Fed

Registry information

Important dates

Study start
2011
Primary completion
2015
Study completion
2015
First posted
Jun 11, 2010
Registry last updated
Jul 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.